CIK 1365216

Sucampo Pharmaceuticals, Inc.

EDGAR filings

Customers

1 disclosed

Suppliers

None disclosed

Largest customer

63%

TAK · 3M to 2017-09-30

Named-customer revenue

$38.6M

1 customer · 3M to 2017-09-30

Latest period

Sep 30, 2017

10-Q filed 2017-11-01

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Customers 1

Companies Sucampo Pharmaceuticals, Inc. discloses as major customers, as a share of Sucampo Pharmaceuticals, Inc. revenue. 1 active, 0 lapsed.

Company	% of Sucampo Pharmaceuticals, Inc. revenue	Est. revenue	Period	Trend	Status	Source
TAK TAKEDA PHARMACEUTICAL CO LTD	63%	$38.6M	3M 2017-09-30	−2.4pp	Active	10-Q 2017-11-01
Revenues from Takeda, an unrelated party, accounted for 63.0% and 65.7% of the Company’s total revenues for the three months ended September 30, 2017 and 2016, respectively, and 62.6% and 65.6% of the Company’s total revenues for the nine months ended September 30, 2017 and 2016, respectively. 10-Q filed 2017-11-01 Period 3M 2017-07-01 to 2017-09-30 (63%), 3M 2016-07-01 to 2016-09-30 (65.7%)Accession 0001171843-17-006456 Revenues from Takeda, an unrelated party, accounted for 65.4% and 69.3% of the Company’s total revenues for the three months ended June 30, 2017 and 2016, respectively, and 62.3% and 65.5% of the Company’s total revenues for the six months ended June 30, 2017 and 2016, respectively. 10-Q filed 2017-08-02 Period 3M 2017-04-01 to 2017-06-30 (65.4%), 3M 2016-04-01 to 2016-06-30 (69.3%)Accession 0001171843-17-004571 Revenues from Takeda, an unrelated party, accounted for 59.1% and 61.5% of the Company’s total revenues for the three months ended March 31, 2017 and 2016, respectively. 10-Q filed 2017-05-03 Period 3M 2017-01-01 to 2017-03-31 (59.1%), 3M 2016-01-01 to 2016-03-31 (61.5%)Accession 0001171843-17-002594 · We recognize product sales revenue from the supply of AMITIZA to Takeda at a negotiated supply price. 10-K filed 2017-03-08 Period FY 2016-01-01 to 2016-12-31 (63.9%), FY 2015-01-01 to 2015-12-31 (63.3%), FY 2014-01-01 to 2014-12-31 (71.3%)Accession 0001171843-17-001354 Revenues from Takeda, an unrelated party, accounted for 66.3% and 62.4% of the Company’s total revenues for the three months ended September 30, 2015 and 2014, respectively, and 60.4% and 66.7% for the nine months ended September 30, 2015 and 2014, respectively. 10-Q filed 2015-11-04 Period 3M 2015-07-01 to 2015-09-30 (66.3%), 3M 2014-07-01 to 2014-09-30 (62.4%)Accession 0001171843-15-005981 Revenues from Takeda, an unrelated party, accounted for 69.3% and 53.6% of the Company’s total revenues for the three months ended June 30, 2016 and 2015, respectively, and 65.5% and 57.4% for the six months ended June 30, 2016 and 2015, respectively. 10-Q filed 2016-08-03 Period 3M 2015-04-01 to 2015-06-30 (53.6%)Accession 0001171843-16-011464 Revenues from Takeda, an unrelated party, accounted for 61.5% and 61.8% of the Company’s total revenues for the three months ended March 31, 2016 and 2015, respectively. 10-Q filed 2016-05-05 Period 3M 2015-01-01 to 2015-03-31 (61.8%)Accession 0001171843-16-009701 Revenues from Takeda, an unrelated party, accounted for 53.6% and 68.1% of the Company’s total revenues for the three months ended June 30, 2015 and 2014, respectively, and 57.4% and 69.6% for the six months ended June 30, 2015 and 2014, respectively. 10-Q filed 2015-08-05 Period 3M 2014-04-01 to 2014-06-30 (68.1%)Accession 0001171843-15-004344 Revenues from Takeda, an unrelated party, accounted for 63.3%, 71.3% and 81.3% of the Company’s total revenues for the years ended December 31, 2015, 2014 and 2013, respectively. 10-K/A filed 2016-03-16 Period FY 2013-01-01 to 2013-12-31 (81.3%)Accession 0001171843-16-008620 • Along with Takeda and R-Tech, we settled our patent litigation dispute in the U.S. with Anchen Pharmaceuticals, Inc. (Anchen), Par Pharmaceutical, Inc. (Par Pharmaceutical) and Par Pharmaceutical Companies, Inc. (Anchen and the Par Pharmaceuticals entities collectively, Par) with respect to AMITIZA pursuant to a settlement agreement and license agreement allowing us to maintain brand exclusivity during the current term of the North America Takeda Agreement and realize royalty revenue from 2021 to 2027 from generic or authorized generic sales by Par; and 10-K filed 2015-03-09 Period FY 2012-01-01 to 2012-12-31 (74.4%)Accession 0001171843-15-001318

Alerts are coming

Get an email when Sucampo Pharmaceuticals, Inc.'s disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.